Literature DB >> 10428824

Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A.

A V Kazansky1, E B Kabotyanski, S L Wyszomierski, M A Mancini, J M Rosen.   

Abstract

In this study, DNA binding and tyrosine phosphorylation of STAT5A and STAT5B were compared with their subcellular localization determined using indirect immunofluorescence microscopy. Following prolactin activation, both STAT5A and STAT5B were rapidly translocated into the nucleus and displayed a detergent-resistant, punctate nuclear staining pattern. Similar to prolactin induction, src activation resulted in tyrosine phosphorylation and DNA binding of both STAT5A and STAT5B. However, nuclear translocation of only STAT5B but not STAT5A was observed. This selective nuclear translocation appears to be mediated via the carboxyl-terminal sequences in STAT5B. Furthermore, overexpression of a dominant negative kinase-inactive mutant of JAK2 prevented prolactin-induced tyrosine phosphorylation and nuclear translocation of STAT5A and STAT5B but did not block src kinase activation and nuclear translocation of STAT5B. In co-transfection assays, prolactin-mediated activation but not src kinase-mediated activation of STAT5B resulted in the induction of a beta-casein promoter-driven reporter construct. These results suggest that STAT5 activation by src may occur by a mechanism distinct from that employed in cytokine activation of the JAK/STAT pathway, resulting in the selective nuclear translocation of STAT5B.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428824     DOI: 10.1074/jbc.274.32.22484

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

Review 2.  Roles and regulation of stat family transcription factors in human breast cancer.

Authors:  Charles V Clevenger
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

3.  The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

Authors:  Agata Klejman; Steven J Schreiner; Malgorzata Nieborowska-Skorska; Artur Slupianek; Matthew Wilson; Thomas E Smithgall; Tomasz Skorski
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

4.  Regulation of STAT1 nuclear export by Jak1.

Authors:  K Mowen; M David
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

5.  Oct-1 functions as a transactivator in the hormonal induction of beta-casein gene expression.

Authors:  Bing Dong; Chengfei Huang; Defa Li; Feng-Qi Zhao
Journal:  Mol Cell Biochem       Date:  2009-03-06       Impact factor: 3.396

6.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

Review 7.  Signal transducer and activator of transcription 5A/B in prostate and breast cancers.

Authors:  Shyh-Han Tan; Marja T Nevalainen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

8.  Rac1 signaling modulates BCL-6-mediated repression of gene transcription.

Authors:  Patrícia Barros; Peter Jordan; Paulo Matos
Journal:  Mol Cell Biol       Date:  2009-06-01       Impact factor: 4.272

9.  Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo.

Authors:  Kathleen A O'Leary; Fatou Jallow; Debra E Rugowski; Ruth Sullivan; Kerstin W Sinkevicius; Geoffrey L Greene; Linda A Schuler
Journal:  Endocrinology       Date:  2013-09-24       Impact factor: 4.736

10.  Reduced intranuclear mobility of APL fusion proteins accompanies their mislocalization and results in sequestration and decreased mobility of retinoid X receptor alpha.

Authors:  Shuo Dong; David L Stenoien; Jihui Qiu; Michael A Mancini; David J Tweardy
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.